Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Spyre (SYRE) PT Raised to $107 at Stifel
May 5, 2026 4:26 PM EDTStifel analyst Alex Thompson raised the price target on Spyre (NASDAQ: SYRE) to $107.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Following best-in-class UC PoC data for SPY001 (a4B7), SYRE is well-positioned heading into additional PoC cohorts for... More



